GW Suffers Major Blow as U.S. Sinks Bid to Patent Cannabinoids for Epilepsy
Adobe Stock

GW Suffers Major Blow as U.S. Sinks Bid to Patent Cannabinoids for Epilepsy

The patent, which has been embroiled in dispute since 2010, is for "the use of one or more cannabinoids in the treatment of epilepsy."

Subscribe
January 17, 2019

British firm GW Pharmaceuticals is licking its wounds after U.S. judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle.

The US Patent Trial and Appeal Board, an administrative law body of the national patent office, denied patent US9066920B2 on January 3, siding with petitioner Insys, a rival biotech firm.

The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”. More particularly, to the use of one or a combination of cannabinoids, CBD oil, in the treatment of generalized or partial seizures.

Read more